Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya3366910.26442/00403660.2019.05.000169Editorial articleПередовая статьяResearch ArticleAlflutop - in modern symptom - modifying osteoarthritis therapyАлфлутоп - в современной симптом - модифицирующей терапии остеоартритаDrozdovV NДроздовВладимир Николаевич

д.м.н., проф., проф. каф. клинической фармакологии и пропедевтики внутренних болезней лечебного фак-та ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет)

vndrozdov@yandex.ruShikhE VШихЕвгения Валерьевна

д.м.н., проф., зав. каф. клинической фармакологии и пропедевтики внутренних болезней лечебного фак-та ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет)

SerebrovaS YСереброваСветлана Юрьевна

д.м.н., проф. каф. клинической фармакологии и пропедевтики внутренних болезней лечебного фак-та ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет)

AbrosimovA GАбросимовАнатолий Георгиевич

к.м.н., доцент каф. клинической фармакологии и пропедевтики внутренних болезней лечебного фак-та ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет)

StarodubtsevA KСтародубцевАлексей Константинович

д.м.н., проф., проф. каф. клинической фармакологии и пропедевтики внутренних болезней лечебного фак-та ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет)

Clinical pharmacology and internal medicine propaedeutics of I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Department of general medicineФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)15052019915VOL 91, NO5 (2019)ТОМ 91, №5 (2019)13414016042020Copyright ©; 2019, Consilium MedicumCopyright ©; 2019, ООО "Консилиум Медикум"2019Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/33669

One of the serious problems during the treatment of osteoarthritis (OA) is the developing of adverse drug events during therapy. Nonsteroidal anti - inflammatory drugs (NSAIDs) are the first drugs with the high incidence and severity of adverse events. This article describes OA treatment strategies approaches for OA are presented using the complex drug Alflutop, which has a composition similar to the human hyaline cartilage. The drug has anti - inflammatory and analgesic effects, normalizes the function of the affected joints, improves the quality of patients’ life, also has a structure - modifying effect. Such therapy is safe, well tolerable for patients, and can be used used as a starting complex OA treatment.

Одной из серьезных проблем лечения остеоартрита (ОА) является развитие нежелательных явлений при назначении медикаментозной терапии, и первое место по частоте и тяжести нежелательных лекарственных реакций принадлежит нестероидным противовоспалительным препаратам (НПВП). В статье представлены подходы к лечению ОА с использованием комплексного препарата Алфлутоп, который имеет состав, аналогичный матриксу гиалинового хряща. Препарат обладает противовоспалительным и обезболивающим действием, нормализует функцию пораженных суставов, улучшает качество жизни пациентов, а также обладает структурно - модифицирующим эффектом. Такая терапия является безопасной, хорошо переносится пациентами и снижает ежедневную потребность в НПВП и может быть использована в стартовой комплексной терапии ОА.

osteoarthritistherapydaily consumption of nonsteroidal anti-inflammatory drugscomplex therapyостеоартриттерапияпотребность в нестероидных противовоспалительных препаратахкомплексная терапияNoyszewski E.A, Wroblewski K, Dodge G.R, Kudchodkar S, Beers J, Sarma A.V, et al. Preferential incorporation of glucosamine into the galactosamine moieties of chondroitin sulfate in articular cartilage explants. Arthritis Rheum. 2001;44:1089-95. https://doi.org/10.1002/1529-0131(200105)44:5<1089::AID-ANR189>3.0.CO;2-9Bassleer C, Rovati L.C, Franchimont P. Glucosamine sulfate stimulates proteoglycan production in human chondrocytes in vitro. Osteoarthritis Cartilage. 1998;6:427-34. https://doi.org/10.1053/joca.1998.0146Piperno M, Reboul P, Helio Le, Graverand M.P, Peschard M.J, Annefeld M, Richard M, et al. Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthritis Cartilage. 2000;8:207-12. https://doi.org/10.1053/joca.1999.0291Dodge G.R, Jimenez S.A. Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cartilage. 2003;11:424-32. https://doi.org/10.1016/s1063-4584(03)00052-9Mroz P.J, Silbert J.E. Use of 3H-glucosamine and 35S-sulfate with cultured human chondrocytes to determine the effect of glucosamine concentration on formation of chondroitin sulfate. Arthritis Rheum. 2004;50:3574-9. https://doi.org/10.1002/art.20609Biggee B.A, Blinn C.M, Mc Alindon T.E, Nuite M, Silbert J.E. Low levels of human serum glucosamine after ingestion of glucosamine sulfate relative to capability for peripheral effectiveness. Ann Rheum Dis. 2006;65:222-6. https://doi.org/10.1136/ard.2005.036368Varghese S, Theprungsirikul P, Sahani S, Hwang N, Yarema K.J, Elisseeff J.H. Glucosamine modulates chondrocyte proliferation, matrix synthesis, and gene expression. Osteoarthritis Cartilage. 2007;15:59-68. https://doi.org/10.1016/ j.joca.2006.06.008Gouze J.N, Bordji K, Gulberti S, Terlain B, Netter P, Magdalou J, et al. Interleukin-1beta down - regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1beta - mediated effects in rat chondrocytes. Arthritis Rheum. 2001;44:351-60. https://doi.org/10.1002/1529-0131(200102)44:2%3C351:: aid-anr53%3E3.0.co;2-mChiusaroli R, Piepoli T, Zanelli T, Ballanti P, Lanza M, Rovati L.C, et al. Experimental pharmacology of glucosamine sulfate. Int J Rheumatol. 2011: 939265 [Epub]. https://doi.org/10.1155/2011/939265Imagawa K, de Andrés M.C, Hashimoto K, Pitt D, Itoi E, Goldring M.B, et al. The epigenetic effect of glucosamine and a nuclear factor - kappa B (NF-kB) inhibitor on primary human chondrocytes - implications for osteoarthritis. Biochem Biophys Res Commun. 2011;405:362-7. https://doi.org/10.1016/j.bbrc. 2011.01.007Maneiro E, Fernández Sueiro J, Lema D, de Toro F, Galdo F, Blanco F. Efecto del condroitín sulfato sobre la producción de óxido nítrico por los condrocitos humanos artrósicos. Rev Esp Reumatol. 2001;28:12-7. https://doi.org/10.39 89/mc.1961.v11.i103.1883Vergés J, Montell E, Martinez G, Heroux L, du Souich P. Chon - droitin sulfate reduces nuclear translocation factor NF-kappaB and does not modify the activation state of activating protein-1 (AP-1) (Abstract). Osteoarthritis Cartilage. 2004;12:194. https://doi.org/10.1016/s1063-4584(08)60572-5Jomphe C, Gabriac M, Hale T.M, Heroux L, Trudeau L.E, Deblois D, et al. Chondroitin sulfate inhibits the nuclear translocation of nuclear factor - kappaB in interleukin-1beta - stimulated chondrocytes. Basic Clin Pharmacol Toxicol. 2008;102:59-65. https://doi.org/10.1111/j.1742-7843.2007.00158.xCaraglia M, Beninati S, Giuberti G, D’Alessandro A.M, Lentini A, Abbruzzese A, et al. Alternative therapy of earth elements increases the chondroprotective effects of chondroitin sulfate in mice. Exp Mol Med. 2005;37:476-81. https://doi.org/10.1038/emm.2005.58Bassleer C.T, Combal J.P, Bougaret S, Malaise M. Effects of chondroitin sulfate and interleukin-1 beta on human articular chondrocytes cultivated in clusters. Osteoarthritis Cartilage. 1998;6:196e204. https://doi.org/10.1053/joca.199 8.0112Uebelhart D, Thonar E.J, Zhang J, Williams J.M. Protective effect of exogenous chondroitin 4,6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthritis Cartilage. 1998;6(Suppl A):6-13. https://doi.org/10.1016/ s1063-4584(98)80005-8Wang L, Wang J, Almqvist K.F, Veys E.M, Verbruggen G. Influence of polysulphated polysaccharides and hydrocortisone on the extracellular matrix metabolism of human articular chondrocytes in vitro. Clin Exp Rheumatol. 2002;20:669-76. https://doi.org/10.1016/s1063-4584(03)00168-7Orth M.W, Peters T.L, Hawkins J.N. Inhibition of articular cartilage degradation by glucosamine HCl and chondroitin sulphate. Equine Vet J Suppl. 2010;34:224-9. https://doi.org/10.1111/j.2042-3306.2002.tb05423.xChan P.S, Caron J.P, Orth M.W. Effect of glucosamine and chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1- challenged bovine articular cartilage explants. Am J Vet Res. 2005;66:1870-6. https://doi.org/10.2460/ajvr.2005.66.1870Chou M.M, Vergnolle N, Mc Dougall J.J, Wallace J.L, Marty S, Teskey V, et al. Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin- 1beta, matrix metalloprotease-9, and cartilage damage in arthritis. Exp Biol Med. 2005;230:255-62. https://doi.org/10.1177/153 537020523000405Monfort J, Nacher M, Montell E, Vila J, Verges J, Benito P. Chondroitin sulfate and hyaluronic acid (500e730 kDa) inhibit stromelysin-1 synthesis in human osteoarthritic chondrocytes. Drugs Exp Clin Res. 2005;31:71-6. https:// doi.org/10.1016/s1699-258x(05)72734-0Baici A, Bradamante P. Interaction between human leukocyte elastase and chondroitin sulfate. Chem Biol Interact. 1984;51:1-11. https://doi.org/10.10 16/0009-2797(84)90015-2Baici A, Lang A. Cathepsin B secretion by rabbit articular chondrocytes: modulation by cycloheximide and glycosami - noglycans. Cell Tissue Res. 1990;259:567-73. https://doi.org/10.1007/bf01740785Verbruggen G, Veys E.M. Influence of sulphated glycosamino - glycans upon proteoglycan metabolism of the synovial lining cells. Acta Rhumatol Belg. 1977;1:75-92.Nishikawa H, Mori I, Umemoto J. Influences of sulfated glycosaminoglycans on biosynthesis of hyaluronic acid in rabbit knee synovial membrane. Arch Biochem Biophys. 1985;240:146-53. https://doi.org/10.1016/0003-9861(85) 90017-7Nishikawa H, Mori I, Umemoto J. Glycosaminoglycan polysulfate - induced stimulation of hyaluronic acid synthesis in rabbit knee synovial membrane: involvement of binding protein and calcium ion. Arch Biochem Biophys. 1988;266:201-9. https://doi.org/10.1016/0003-9861(88)90251-2Chan P.S, Caron J.P, Rosa G.J, Orth M.W. Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants. Osteoarthritis Cartilage. 2005;13:387-94. https://doi.org/10.1016/j.joca.2005.01.003Chan P.S, Caron J.P, Orth M.W. Short - term gene expression changes in cartilage explants stimulated with interleukin beta plus glucosamine and chondroitin sulfate. J Rheumatol. 2006;33:1329-40.Tat S.K, Pelletier J.P, Vergés J, Montell E, Lajeunesse D, Fahmi H, et al. Chondroitin and glucosamine sulfate in combination decrease the pro - resorptive properties of human osteoarthritis subchondral bone osteoblasts. Arthritis Res Ther. 2007;9:R117. https://doi.org/10.1186/ar2325Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64:669-81. https://doi.org/10. 1136/ard.2004.028886Zhang W, Moskowitz R.W, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence - based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16:137-62. https://doi.org/10.1016/j.joca.2008.04.019Zhang W, Moskowitz R.W, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part I: Critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage. 2007;15:981-1000. https://doi.org/10.1016/j.joca.20 08.04.019Zhang W, Nuki G, Moskowitz R.W, et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010;18:476-99.Hochberg M.C, Altman R.D, April K.T, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64:465-74. https://doi.org/10.1002/acr.21596Mc Alindon T.E, Bannuru R.R, Sullivan M.C, et al. OARSI guidelines for the non - surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22(3):363-88. https://doi.org/10.1016/ j.joca.2014.01.003Meulyzer M, Vachon P, Beaudry F, Vinardell T, Richardy H, Beauchamp G, Laverty S. Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride. Osteoarthritis and Cartilage. 2008;16:973-9. https://doi.org/10. 1016/j.joca.2008.01.006Persiani S, Rotini R, Trisolino G, Rovati L.C, Locatelli M, Paganini D, Antonioli D, Roda A. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. OsteoArthritis and Cartilage. 2007;15:764-72. https://doi.org/10.1016/ j.joca.2007.01.019Biggee B.A, Blinn C.M, Mc Alindon T.E, Nuite M, Silbert J.E. Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Ann Rheum Dis. 2006;65:222-6. doi: 10.1136/ard.2005.036368Volpi N. Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers. OsteoArthritis and Cartilage. 2003;11:433-41. https://doi.org/10.1016/s1063-4584(03)00051-7Laura Olariu, Brindusa Dumitriu, Diana Manuela Ene, Alexey Pavlov, Natalya Pyatigorskaya, Natalia Rosoiu. Alflutop Modulates “In Vitro” Relevant Mechanisms of Osteoarthritic Pathology. Annals Series on Bio - logical Sciences. 2017 Academy of Romanian Scientists. 2017;6(1):82-99. ISSN 2285 - 4177Laura Olariu, Brindusa Dumitriu, Emilia Buse, Natalia Rosoiu. The ”In Vitro” Effect Of Alflutop Product On Some Extracellular Signaling Factors Involved In The Osteoarthicular Pathology Inflammation The ”In Vitro” Effect Of Alflutop® Product On Some Extracellular Signaling Factors Involved In The Osteoarthicular Pathology Inflammation. Academy of Romanian Scientists. Annals Series on Biological Sciences. 2015;4(2):7-18. ISSN 2285 - 4177 Online Edition; Original Paper, Received for publication, September, 15, 2015. Accepted, December, 01, 2015Алексеева Л.И., Шарапова Е.П., Таскина Е.А. и др. Многоцентровое слепое рандомизированное плацебоконтролируемое исследование симптом - и структурно - модифицирующего действия препарата алфлутоп у больных остеоартрозом коленных суставов. Сообщение 1 - Оценка симптом - модифицирующего действия препарата. Научно - практическая ревматология. 2013;51(5):532-8. https://doi.org/10.14412/1995-4484-2013-1545Hawkey C.J. Cyclooxygenase inhibition: between the devil and the deep blue sea. GUT. 2002;50(suppl.3):1125-30. https://doi.org/10.1136/gut.50. suppl_3.iii25Taha A.S, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti - inflammatory drugs. N Engl J Med. 1996;334:1435-9.Agrawal N.M, Van Kerchkhove H, Erhardt L.J, Geis G.S. Dig Dis Sci. 1995;40:1125-31. https://doi.org/10.1007/bf02064210Labeling Guidance Diclofenac Sodium February 1995; www.fda.gov (accessed 8/3/01) Traversa G, et al. Cohort study of hepatotoxicity associated with nimesulide and other non - steroidal anti - inflammatory drugs. BMJ. 2003;327:18-22.Trechot P, et al. Incidence of hepatitis induced by non - steroidal anti - inflammatory drugs (NSAID). Ann Rheum Dis. 1996 Dec;55(12):936.Boelsterli U. Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Saf. 2002;25:633-48.Kumar S. Drug linked to child deaths is still available in India. BMJ. 2003;326:70.Светлова М.С., Игнатьев В.К. Применение алфлутопа в лечении больных остеоартрозом. Клиническая медицина. 2004;6:52-5.Дроздов В.Н., Коломеец Е.В. Применение Алфлутопа у больных остеоартрозом с гастропатией, развившейся на фоне лечения НПВП. Фарматека. 2005;20:125-8.Emilia Buse, Brandusa Dumitriu, Laura Olariu, Diana Ene, Mihai Bojinca, Toma Papacocea. Cellular and molecular activity of a standardized small sea fish extract in an experimental model of primary human cartilage cells. Roman J of Rheumatol. 2018;27(1):23-31.Laura Olariu, Brindusa Dumitriu, Luiza Craciun, Emilia Buse, Natalia Rosoiu, Mihai Bojinca, Toma Papacocea. The In Vitro Influence of A Pharmaceutically Active Small Sea Fish Extract on Apoptosis and Proliferation Mechanisms Amplified by Inflammatory Conditions. Manuscript received: November 2017. FARMACIA. 2018;66(3).